Clin Psychopharmacol Neurosci.
2019 Nov;17(4):495-502. 10.9758/cpn.2019.17.4.495.
The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study
- Affiliations
-
- 1Department of Psychiatry, Korea University College of Medicine, Seoul, Korea.
- 2Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea. pae@catholic.ac.kr
- 3International Health Care Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- 4Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA.
- 5Global Medical Education, New York, NY, USA.
- 6Cell Death Disease Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- KMID: 2464715
- DOI: http://doi.org/10.9758/cpn.2019.17.4.495
Abstract
OBJECTIVE
The present study aimed to observe potential benefit of aripiprazole augmentation in the treatment of major depressive disorder with mixed specifier (MDDM) in naturalistic treatment setting.
METHODS
Data were collected from MDDM patients using a retrospective chart review for 8 weeks (week -8 and week 0) in routine practice. All patients were on current antidepressants upon starting of aripiprazole. Patients were treated without restriction of doses of aripiprazole. The primary endpoint was the mean change of Montgomery-Ã…sberg Depression Rating Scale (MADRS) total scores along with various secondary endpoint measures.
RESULTS
In total 38 patients were analyzed. The changes of MADRS, Clinical Global Impression (CGI)-severity, Young Mania Rating Scale, Sheehan Disability Scale, and CGI-clinical benefit total scores from baseline to the endpoint were −7.1, −0.8, −4.9, −4.1, and −3.6, respectively (all p < 0.0001). At the endpoint, the responder and remitter rates by MADRS score criteria were approximately 32% and 21%, respectively.
CONCLUSION
The present findings have clearly shown the effectiveness and tolerability of aripiprazole augmentation for MDDM patients in routine practice. The present study warrants subsequent, adequately-powered, well-controlled studies for generalizability near future.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Mixed-Features Specifier of Major Depressive Disorder in DSM-5: Is It Practical?
- Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice
- Difference in Treatment Outcome in Hospitalized Major Depression Patients with versus without Anxious Distress Specifier in DSM-5
- Changes in Aripiprazole Usage in the Psychiatric Inpatients at a University Hospital between 2004-2008 and 2009-2013
- Successful Early Lamotrigine and Aripiprazole Augmentation of Clomipramine in Severe Obsessive-compulsive Disorder
